4/26
09:00 am
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/24
03:40 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/20
12:00 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/18
03:45 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/16
03:20 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/15
05:06 pm
zvra
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting [Yahoo! Finance]
Low
Report
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting [Yahoo! Finance]
4/15
05:01 pm
zvra
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Low
Report
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
4/12
09:30 am
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/10
12:00 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/10
07:30 am
zvra
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Low
Report
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
4/8
07:04 pm
zvra
Attention Zevra Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Medium
Report
Attention Zevra Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
4/8
03:27 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/4
06:20 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/3
09:00 pm
zvra
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
Medium
Report
ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
4/3
08:08 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
4/2
05:54 pm
zvra
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
Medium
Report
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
4/2
03:39 pm
zvra
Investigation Into Zevra Therapeutics, Inc. (ZVRA) Announced by Holzer & Holzer, LLC
Low
Report
Investigation Into Zevra Therapeutics, Inc. (ZVRA) Announced by Holzer & Holzer, LLC
4/2
03:30 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/2
08:19 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at Maxim Group from $12.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at Maxim Group from $12.00 to $18.00. They now have a "buy" rating on the stock.
4/1
05:02 pm
zvra
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
4/1
09:01 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/28
04:32 pm
zvra
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
High
Report
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
3/26
04:30 pm
zvra
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
High
Report
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
3/25
04:30 pm
zvra
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/18
07:30 am
zvra
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
Low
Report
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024